Marker Therapeutics (MRKR) Total Non-Current Liabilities (2011 - 2023)

Marker Therapeutics (MRKR) has 10 years of Total Non-Current Liabilities data on file, last reported at $2.9 million in Q2 2023.

• Total Non-Current Liabilities for Q2 2023 came in at $2.9 million, down 73.0% year-over-year; the trailing twelve-month figure through Jun 2023 was $2.9 million (down 73.0% YoY), and the FY2022 annual result was $7.0 million, down 37.42% from the prior year.
• Total Non-Current Liabilities slipped to $2.9 million in Q2 2023 per MRKR's latest filing, from $6.8 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $11.9 million in Q3 2020 and troughed at $226111.0 in Q1 2020.
• A 5-year average of $7.0 million and a median of $8.1 million in 2020 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2021 and 2023: Total Non-Current Liabilities surged 5083.22% in 2021, then slumped 73.0% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $280247.0 in 2019, then soared by 4134.99% to $11.9 million in 2020, then declined by 5.23% to $11.2 million in 2021, then plunged by 37.42% to $7.0 million in 2022, then plunged by 58.51% to $2.9 million in 2023.
• Business Quant data shows MRKR's Total Non-Current Liabilities at $2.9 million in Q2 2023, $6.8 million in Q1 2023, and $7.0 million in Q4 2022.